These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30847387)

  • 1. MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring
    Fu H; Cheng L; Jin Y; Cheng L; Liu M; Chen L
    Mol Ther Oncolytics; 2019 Mar; 12():235-245. PubMed ID: 30847387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF
    Fu H; Cheng L; Sa R; Jin Y; Chen L
    J Cell Mol Med; 2020 Mar; 24(6):3336-3345. PubMed ID: 31970877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
    Cheng L; Jin Y; Liu M; Ruan M; Chen L
    Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
    Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
    Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
    [No Abstract]   [Full Text] [Related]  

  • 5. Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells.
    Zhang H; Chen D
    Thyroid Res; 2018; 11():13. PubMed ID: 30337961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells.
    Cheng W; Liu R; Zhu G; Wang H; Xing M
    J Clin Endocrinol Metab; 2016 Mar; 101(3):962-71. PubMed ID: 26751190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer.
    Zhang Z; Liu D; Murugan AK; Liu Z; Xing M
    Endocr Relat Cancer; 2014 Apr; 21(2):161-73. PubMed ID: 24243688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib.
    Jafri S; Yaqub A
    Cureus; 2021 Aug; 13(8):e17488. PubMed ID: 34595070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
    Rothenberg SM; McFadden DG; Palmer EL; Daniels GH; Wirth LJ
    Clin Cancer Res; 2015 Mar; 21(5):1028-35. PubMed ID: 25549723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NADPH Oxidase NOX4 Is a Critical Mediator of BRAF
    Azouzi N; Cailloux J; Cazarin JM; Knauf JA; Cracchiolo J; Al Ghuzlan A; Hartl D; Polak M; Carré A; El Mzibri M; Filali-Maltouf A; Al Bouzidi A; Schlumberger M; Fagin JA; Ameziane-El-Hassani R; Dupuy C
    Antioxid Redox Signal; 2017 May; 26(15):864-877. PubMed ID: 27401113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
    Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and
    Anekpuritanang T; Uataya M; Claimon A; Laokulrath N; Pongsapich W; Pithuksurachai P
    Onco Targets Ther; 2021; 14():3959-3969. PubMed ID: 34234465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro.
    Ullmann TM; Liang H; Moore MD; Al-Jamed I; Gray KD; Limberg J; Stefanova D; Buicko JL; Finnerty B; Beninato T; Zarnegar R; Min IM; Fahey TJ
    Surgery; 2020 Jan; 167(1):56-63. PubMed ID: 31585718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study.
    Weber M; Kersting D; Riemann B; Brandenburg T; Führer-Sakel D; Grünwald F; Kreissl MC; Dralle H; Weber F; Schmid KW; Herrmann K; Jentzen W; Grafe H; Rischpler C; Theurer S; Bockisch A; Nagarajah J; Fendler WP
    Clin Cancer Res; 2022 Oct; 28(19):4194-4202. PubMed ID: 35594174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of Radioiodine Uptake by Pulmonary Metastasis of Papillary Thyroid Carcinoma Treated with Dabrafenib and Trametinib.
    Malja E; Kandathil A; Peng F
    Nucl Med Mol Imaging; 2024 Apr; 58(2):92-94. PubMed ID: 38510823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAPK Pathway Inhibitors in Thyroid Cancer: Preclinical and Clinical Data.
    Schubert L; Mariko ML; Clerc J; Huillard O; Groussin L
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
    Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
    Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of BRAF(V600E) mutation on Na(+)/I(-) symporter expression in papillary thyroid carcinoma.
    Dong H; Shen WZ; Yan YJ; Yi JL; Zhang L
    J Huazhong Univ Sci Technolog Med Sci; 2016 Feb; 36(1):77-81. PubMed ID: 26838744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
    Liu J; Liu Y; Lin Y; Liang J
    Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR inhibition enhances the antitumor efficacy of a selective BRAF V600E inhibitor in thyroid cancer cell lines.
    Jia Y; Zhang C; Hu C; Yu Y; Zheng X; Li Y; Gao M
    Oncol Lett; 2018 May; 15(5):6763-6769. PubMed ID: 29616135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.